Market Overview

Benzinga's Top Analyst Calls From April 6, 2018

Share:

These headlines first appeared on Benzinga Pro.

  • Cantor out defending NewLink Genetics Corp (NASDAQ: NLNK), says indoximod is differentiated vs epacadostat in response rates in more heavily pretreated patient population; thinks assuming failure of indoximod may be premature, but understands shares are likely pressured.
  • Buckingham Research maintains Buy rating and $15 target price on Gol Transportes Aéreos (NYSE: GOL), implying 20 percent upside. Says Gol's underlying fundamental outlook is “aided by a continued demand recovery in the context of a heavily restructured supply backdrop and commercial initiatives.”
  • KeyBanc upgrades Halyard Health, Inc. (NYSE: HYH) to Overweight, says upcoming events could raise growth expectations and restructuring and M&A efforts could drive accelerated EPS growth.
  • Mizuho out positive on Nektar Therapeutics (NASDAQ: NKTR), says Incyte’s (NASDAQ: INCY) epacadostat Phase 3 failure is a positive for the company, believes this news raises the possibility of a takeout by BMS in coming months.
  • Imperial Capital maintains Outperform rating on Halcón Resources Corp. (NYSE: HK), says co. is “ready to get active on its West Quito Draw position” following acquisition.

See Also:

Benzinga's Top Upgrades, Downgrades For April 6, 2018

5 Biggest Price Target Changes For Friday

 

Related Articles (GOL + HK)

View Comments and Join the Discussion!

Posted-In: Analyst Color Price Target Intraday Update Analyst Ratings

Latest Ratings

StockFirmActionPT
MOSCleveland ResearchUpgrades23.0
WDCCleveland ResearchUpgrades
MUCleveland ResearchUpgrades
HUBSCanaccord GenuityMaintains325.0
CVCOCraig-HallumUpgrades218.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com